Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBP) Liabilities and Shareholders Equity (2016 - 2025)

Regen BioPharma (RGBP) has disclosed Liabilities and Shareholders Equity for 12 consecutive years, with $237076.0 as the latest value for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 23.85% to $237076.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $878027.0, a 32.35% increase, with the full-year FY2025 number at $274628.0, up 70.49% from a year prior.
  • Liabilities and Shareholders Equity was $237076.0 for Q4 2025 at Regen BioPharma, down from $274628.0 in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.4 million in Q2 2021 to a low of $140770.0 in Q1 2024.
  • A 5-year average of $429955.3 and a median of $279912.0 in 2023 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: soared 1401.6% in 2021, then plummeted 65.38% in 2024.
  • Regen BioPharma's Liabilities and Shareholders Equity stood at $735241.0 in 2021, then tumbled by 43.68% to $414108.0 in 2022, then plummeted by 61.48% to $159528.0 in 2023, then increased by 19.99% to $191416.0 in 2024, then increased by 23.85% to $237076.0 in 2025.
  • Per Business Quant, the three most recent readings for RGBP's Liabilities and Shareholders Equity are $237076.0 (Q4 2025), $274628.0 (Q3 2025), and $196841.0 (Q2 2025).